Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Atherosclerosis Reports
Published in: Current Atherosclerosis Reports 7/2023

13-05-2023 | Coronary Heart Disease

What Is the Optimal Duration of Antiplatelet Therapy for Patients with Coronary Heart Disease?

Authors: Beryl Otieno, Chukwuka Ibecheozor, Marlene S. Williams

Published in: Current Atherosclerosis Reports | Issue 7/2023

Login to get access

Abstract

Purpose of Review

Optimal duration of antiplatelet therapy continues to attract extensive debates and has been progressively adjusted in the setting of advancements in stent design and assessment of patient clinical characteristics. Given the ever-changing landscape of antiplatelet therapy and the multitude of clinical trials that have examined this duration, there are varying scenarios for optimal duration based on patient presentation and risk profile. This review highlights the current concepts and recommendations regarding duration of antiplatelet therapy in coronary heart disease.

Recent Findings

In particular, we review the current data on the use of dual antiplatelet therapy in the different clinical scenarios. Relatively longer dual antiplatelet therapy is perhaps limited to patients with higher risk for cardiovascular events and/or high-risk lesions and shorter durations of dual antiplatelet therapy have been shown to reduce bleeding complications at the same time as stabilization of ischemic endpoints.

Summary

More recent trials have demonstrated the safety of shorter durations of dual antiplatelet therapy in appropriate patients with coronary heart disease.
Literature
1.
Bhatt DL, Lopes RD, Harrington RA. Diagnosis and treatment of acute coronary syndromes: a review. Jama. 2022;327(7):662–75.PubMedCrossRef
2.
Anderson HV, Masri SC, Abdallah MS, Chang AM, Cohen MG, Elgendy IY, et al. 2022 ACC/AHA key data elements and definitions for chest pain and acute myocardial infarction. J Am College Cardiol. 2022;80(17):1660–700.CrossRef
3.
Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: the task force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2019;41(3):407–77.CrossRef
4.
Bianco M, Careggio A, Destefanis P, Luciano A, Perrelli MG, Quadri G, et al. P2Y12 inhibitors monotherapy after short course of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized clinical trials including 29 089 patients. Eur Heart J - Cardiovasc Pharmacother. 2020;7(3):196–205.CrossRef
5.
Feng WH, Hsieh IC, Li YH. P2Y12 inhibitor monotherapy after percutaneous coronary intervention: is it safe to abandon aspirin? Acta Cardiol Sin. 2021;37(1):1–8.PubMedPubMedCentral
6.
Verheugt FWA, Damman P, Damen SAJ, Wykrzykowska JJ, Woelders ECI, van Geuns RM. P2Y12 blocker monotherapy after percutaneous coronary intervention. Neth Heart J. 2021;29(11):566–76.PubMedPubMedCentralCrossRef
7.
Aggarwal D, Bhatia K, Chunawala ZS, Furtado RHM, Mukherjee D, Dixon SR, et al. P2Y(12) inhibitor versus aspirin monotherapy for secondary prevention of cardiovascular events: meta-analysis of randomized trials. Eur Heart J Open. 2022;2(2):oeac019.PubMedPubMedCentralCrossRef
8.
Kang J, Park KW, Lee H, Hwang D, Yang H-M, Rha S-W, et al. Aspirin versus clopidogrel for long-term maintenance monotherapy after percutaneous coronary intervention: the HOST-EXAM extended study. Circulation. 2023;147(2):108–17.PubMedCrossRef
9.
Capodanno D, Angiolillo DJ. Antithrombotic therapy for atherosclerotic cardiovascular disease risk mitigation in patients with coronary artery disease and diabetes mellitus. Circulation. 2020;142(22):2172–88.PubMedCrossRef
10.
Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. Jama. 2013;310(23):2510–22.PubMed
11.
Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG, et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET trial (real safety and efficacy of 3-month dual antiplatelet therapy following endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol. 2012;60(15):1340–8.PubMedCrossRef
12.••
Valgimigli M, Frigoli E, Heg D, Tijssen J, Jüni P, Vranckx P, et al. Dual antiplatelet therapy after PCI in patients at high bleeding risk. New Engl J Med. 2021;385(18):1643–55. Among patients who are at high bleeing risk or who require anticogulation who undergo PCI, DAPT abbreviated to 1 month compared to 3 months is noninferior when examining net adverse clinical events. There is also decreased major or clinically relevant nonmajor bleeding when this option is chosen.PubMedCrossRef
13.
Colombo A, Chieffo A, Frasheri A, Garbo R, Masotti-Centol M, Salvatella N, et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol. 2014;64(20):2086–97.PubMedCrossRef
14.
Gwon H-C, Hahn J-Y, Park KW, Song YB, Chae I-H, Lim D-S, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents. Circulation. 2012;125(3):505–13.PubMedCrossRef
15.
Gilard M, Barragan P, Noryani AAL, Noor HA, Majwal T, Hovasse T, et al. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. J Am Coll Cardiol. 2015;65(8):777–86.PubMedCrossRef
16.
Schulz-Schüpke S, Byrne RA, ten Berg JM, Neumann F-J, Han Y, Adriaenssens T, et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. European Heart J. 2015;36(20):1252–63.CrossRef
17.
Bhatt DL, Fox KAA, Hacke W, Berger PB, Black HR, Boden WE, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. New Engl J Med. 2006;354(16):1706–17.PubMedCrossRef
18.
Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. New Engl J Med. 2014;371(23):2155–66.PubMedCrossRef
19.
Mauri L, Elmariah S, Yeh RW, Cutlip DE, Steg PG, Windecker S, et al. Causes of late mortality with dual antiplatelet therapy after coronary stents. Eur Heart J. 2016;37(4):378–85.PubMed
20.
Palmerini T, Benedetto U, Bacchi-Reggiani L, Della Riva D, Biondi-Zoccai G, Feres F, et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet. 2015;385(9985):2371–82.PubMedCrossRef
21.
22.
Secemsky EA, Yeh RW, Kereiakes DJ, Cutlip DE, Cohen DJ, Steg PG, et al. Mortality following cardiovascular and bleeding events occurring beyond 1 year after coronary stenting: a secondary analysis of the dual antiplatelet therapy (DAPT) study. JAMA Cardiol. 2017;2(5):478–87.PubMedPubMedCentralCrossRef
23.
Hermiller JB, Krucoff MW, Kereiakes DJ, Windecker S, Steg PG, Yeh RW, et al. Benefits and risks of extended dual antiplatelet therapy after everolimus-eluting stents. JACC: Cardiovasc Interv. 2016;9(2):138–47.PubMed
24.
Palmerini T, Bruno AG, Gilard M, Morice M-C, Valgimigli M, Montalescot G, et al. Risk-benefit profile of longer-than-1-year dual-antiplatelet therapy duration after drug-eluting stent implantation in relation to clinical presentation. Circ: Cardiovasc Interv. 2019;12(3):e007541.PubMed
25.
Rapsomaniki E, Thuresson M, Yang E, Blin P, Hunt P, Chung SC, et al. Using big data from health records from four countries to evaluate chronic disease outcomes: a study in 114 364 survivors of myocardial infarction. Eur Heart J Qual Care Clin Outcomes. 2016;2(3):172–83.PubMedPubMedCentralCrossRef
26.
Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, et al. Ticagrelor in patients with stable coronary disease and diabetes. New Engl J Med. 2019;381(14):1309–20.PubMedCrossRef
27.
Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. New Engl J Med. 2015;372(19):1791–800.PubMedCrossRef
28.
Bhatt DL, Steg PG, Mehta SR, Leiter LA, Simon T, Fox K, et al. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet. 2019;394(10204):1169–80.PubMedCrossRef
29.
Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. New Engl J Med. 2019;381(21):2032–42.PubMedCrossRef
30.
Chiarito M, Baber U, Cao D, Sharma SK, Dangas G, Angiolillo DJ, et al. Ticagrelor monotherapy after PCI in high-risk patients With Prior MI: a prespecified TWILIGHT substudy. JACC: Cardiovasc Interv. 2022;15(3):282–93.PubMed
31.•
Kim BK, Hong SJ, Cho YH, Yun KH, Kim YH, Suh Y, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. Jama. 2020;323(23):2407–16. This publication demonstrated the superiority of Ticagrelor monotherapy after 3 months of DAPT compared to 12 months of DAPT.PubMedPubMedCentralCrossRef
32.
Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting. Circulation. 2012;125(16):2015–26.PubMedCrossRef
33.
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New Engl J Med. 2001;345(7):494–502.
34.
Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. New Engl J Med. 2007;357(20):2001–15.PubMedCrossRef
35.
Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New Engl J Med. 2009;361(11):1045–57.PubMedCrossRef
36.
Vranckx P, Valgimigli M, Jüni P, Hamm C, Steg PG, Heg D, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. 2018;392(10151):940–9.PubMedCrossRef
37.
Franzone A, McFadden E, Leonardi S, Piccolo R, Vranckx P, Serruys PW, et al. Ticagrelor alone versus dual antiplatelet therapy from 1 month after drug-eluting coronary stenting. J Am College Cardiol. 2019;74(18):2223–34.CrossRef
38.
Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. Bmj. 2008;336(7644):601–5.PubMedPubMedCentralCrossRef
39.
Hróbjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Hilden J, Boutron I, et al. Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors. CMAJ. 2013;185(4):E201–11.PubMedPubMedCentralCrossRef
40.
Costa F, van Klaveren D, James S, Heg D, Räber L, Feres F, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017;389(10073):1025–34.PubMedCrossRef
41.
Yeh RW, Secemsky EA, Kereiakes DJ, Normand S-LT, Gershlick AH, Cohen DJ, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. Jama. 2016;315(16):1735–49.PubMedPubMedCentralCrossRef
42.
Chichareon P, Baber U, Modolo R, Chang C-C, Kogame N, Takahashi K, et al. Predictive ability of the PARIS risk score in all-comers patients undergoing pci with drug eluting stents: external validation in the global leaders study. J Am College Cardiol. 2019;73(9_Supplement_1):245.CrossRef
43.
Ueda P, Jernberg T, James S, Alfredsson J, Erlinge D, Omerovic E, et al. External validation of the DAPT score in a nationwide population. J Am College Cardiol. 2018;72(10):1069–78.CrossRef
44.
Sibbing D, Aradi D, Alexopoulos D, Ten Berg J, Bhatt DL, Bonello L, et al. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y(12) receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc Interv. 2019;12(16):1521–37.PubMedCrossRef
45.
Räber L, Magro M, Stefanini GG, Kalesan B, van Domburg RT, Onuma Y, et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation. 2012;125(9):1110–21.PubMedCrossRef
46.
Han J-K, Hwang D, Yang S, Park S-H, Kang J, Yang H-M, et al. Comparison of 3-6 month versus 12 month dual antiplatelet therapy after coronary intervention using the contemporary drug-eluting stents with ultrathin struts: the HOST-IDEA randomized clinical trial. Circulation.0(0).
Metadata
Title
What Is the Optimal Duration of Antiplatelet Therapy for Patients with Coronary Heart Disease?
Authors
Beryl Otieno
Chukwuka Ibecheozor
Marlene S. Williams
Publication date
13-05-2023
Publisher
Springer US
Published in
Current Atherosclerosis Reports / Issue 7/2023
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-023-01108-z

Other articles of this Issue 7/2023

Current Atherosclerosis Reports 7/2023 Go to the issue

ReviewPaper

The Pandemic of Coronary Heart Disease in South Asia: What Clinicians Need to Know

ReviewPaper

Childhood Obesity and Cardiovascular Disease Risk

ReviewPaper

Eggs and Cardiovascular Disease Risk: An Update of Recent Evidence

ReviewPaper

Double-Trouble: Atherosclerotic Risk Factors and Congenital Heart Disease

ReviewPaper

The Role of Cardiac PET in Diagnosis and Prognosis of Ischemic Heart Disease: Optimal Modality Across Different Patient Populations

ReviewPaper

Lipoprotein Apheresis: Current Recommendations for Treating Familial Hypercholesterolemia and Elevated Lipoprotein(a)
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits